Skip to main content
SpringerLink
Log in

Aktuelles zur Histopathologie des Harnblasenkarzinoms

Update on urothelial carcinoma histopathology

  • Schwerpunkt: Uropathologie
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Die Harnblasenkarzinome umfassen eine heterogene Gruppe von Erkrankungen mit sehr unterschiedlichem klinischen Ausgang: 70–80% der Harnblasenkarzinome sind genetisch stabil und haben eine günstige Prognose, 20–30% sind genetisch instabil und werden schnell muskelinvasiv. Diese Beobachtungen liegen der aktuellen WHO-Klassifikation von 2004 zugrunde, nach der die malignen Neoplasien nur noch in „low grade“ und „high grade“ differenziert werden. Neben der TNM-Klassifikation und dem Grading haben auch Mutationen von Genen wie p53, Fibroblasten-Wachstumsfaktor-Rezeptor 3 (FGFR3) und Phosphatidylinositol-3-Kinase (PIK 3 CA) eine prognostische Relevanz.

Abstract

Urothelial carcinoma comprise a heterogenous group of diseases with very different clinical outcome: 70%–80% of urothelial carcinoma are genetically stable and associated with a favorable prognosis, while 20%–30% are genetically unstable and have a high progression rate. Therefore, the current WHO Classification (2004) reduces the histologic grade to simply ‘low grade’ and ‘high grade’. In addition to TNM classification and histologic grade, genetic factors such as p53 mutations, fibroblast growth factor receptor 3 (FGFR3) and phosphatidylinositol-3-kinase (PIC 3 CA) are relevant in a patient’s prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Eble JN, Sauter G, Epstsein JI, Sesterhenn IA (eds) (2004) Tumors of the urinary system and male genital tract. WHO Classification of Tumours. Pathology & Genetics. IARC Press, Lyon

  2. Epstein JI, Amin MB, Reuter VE (eds) (2004) Bladder biopsy interpretation. Lippincott Williams & Wilkins, Philadelphia

  3. Grignon DJ (1997) Neoplasms of the urinary bladder. In: Bostwick DG, Eble JE (eds) Urological surgical pathology. Mosby-Year Book, St. Louis, pp 214–305

  4. Hafner C, Knuechel R, Stoehr R, Hartmann A (2002) Clonality of multifocal urothelial carcinomas: 10 years of mulecular genetic studies. Int J Cancer 101: 1–6

    Article  PubMed  CAS  Google Scholar 

  5. Hafner C, Knuechel R, Zanardo L et al. (2001) Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 20: 4910–4915

    Article  PubMed  CAS  Google Scholar 

  6. Hungerhuber E, Stepp H, Kriegmair M et al. (2007) Seven years‘ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69: 260–264

    Article  PubMed  Google Scholar 

  7. Jones TD, Cheng L (2006) Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol 175: 1995–2003

    Article  PubMed  Google Scholar 

  8. Leissner J, Hohenfellner R, Thüroff JW, Wofl HK (2000) Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. Br J Urol 85: 817–823

    CAS  Google Scholar 

  9. López-Knowles E, Hernández S, Malats N et al. (2006) PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66: 7401–7404

    Article  PubMed  Google Scholar 

  10. Mitra AP, Datar RH, Cote RJ (2006) Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 24: 5552–5564

    Article  PubMed  CAS  Google Scholar 

  11. Obermann EC, Junker K, Stoehr R et al. (2003) Frequent genetic alterations in flat urothelial hyperplasia and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 199: 50–57

    Article  PubMed  CAS  Google Scholar 

  12. Stoehr R, Hartmann A (2007) Histopathologie und Molekulargenetik des Harnblasenkarzinoms. Onkologe 12: 1058–1066

    Article  Google Scholar 

  13. Stoehr R, Knuechel R, Boecker J et al. (2002) Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones. Lab Invest 82: 1553–1561

    PubMed  CAS  Google Scholar 

  14. Lindemann-Docter K, Knüchel-Clarke R (2008) Histopathologie des Harnblasenkarzinoms. Entscheidend für das Management der betroffenen Patienten. Urologe 47: 627–638

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Die korrespondierende Autorin gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Institut für Pathologie, Universitätsklinikum RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland

    K. Lindemann-Docter &  R. Knüchel

Authors
  1. K. Lindemann-Docter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Knüchel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Knüchel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lindemann-Docter, K., Knüchel, R. Aktuelles zur Histopathologie des Harnblasenkarzinoms. Pathologe 29, 331–338 (2008). https://doi.org/10.1007/s00292-008-1012-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-008-1012-4

Schlüsselwörter

Keywords

Search

Navigation